SABCS Voice of China | Professors Qiang Liu and Yaping Yang: Final Results of the National Multicenter Clinical Study on AC*4 Sequential T*4 Combined with Full-Course Dual-Target Neoadjuvant Treatment for HER2-Positive Breast Cancer Disclosed

2024.04.16
Led by Professor Qiang Liu and Professor Yaping Yang from the Sun Yat-sen Memorial Hospital's Breast Tumor Hospital at Sun Yat-sen University, the final clinical study results of a new neoadjuvant treatment regimen for HER2-positive breast cancer were disclosed for the first time. The results were presented in the form of a POSTER at the SABCS conference to scholars worldwide. The study demonstrates that the regimen, based on pegylated liposomal doxorubicin as part of the AC*4 protocol followed by a T*4 chemotherapy regimen combined with a full-course dual-target treatment, offers good antitumor efficacy and cardiac safety as a neoadjuvant treatment for patients with HER2-positive breast cancer. This article introduces the research.
SABCS Voice of China | Professor Jian Liu: A New Strategy for Treating HER2-Positive Advanced Breast Cancer in China

SABCS Voice of China | Professor Jian Liu: A New Strategy for Treating HER2-Positive Advanced Breast Cancer in China

2024.04.16
Currently, the combination of docetaxel, trastuzumab, and pertuzumab is the standard first-line treatment for HER2-positive metastatic breast cancer (MBC), but still, 60% of patients experience disease progression after 2 years of treatment. The second-line treatment standards include DS-8201, T-DM1, TKIs, etc., but these options still have their limitations and do not fully meet clinical treatment needs. Therefore, the team led by Professor Jian Liu from Fujian Provincial Tumor Hospital explored a second-line treatment regimen combining pyrotinib with inetetamab(the "Chinese Dual Target") + vinorelbine. The research results were included in the 2023 SABCS conference (Abstract number: PO1-04-05). Tumor Outlook invited Professor Jian Liu to introduce this study

SABCS Voice of China | Teams led by Professors Yuanting Gu and Jingruo Li Announce Results of CDK4/6 Inhibitor Combined with Letrozole as Neoadjuvant Treatment for Early or Locally Advanced HR+/HER2- Breast Cancer

2024.04.16
The results of a single-arm, multicenter, prospective exploratory clinical study on the neoadjuvant treatment of HR-positive, HER2-negative (HR+/HER2-) breast cancer with Dalpiciclib combined with Letrozole, led by Professor Yuanting Gu and Professor Jingruo Li from the First Affiliated Hospital of Zhengzhou University, were selected for poster presentation at the 2023 SABCS conference. The unveiling of these results has attracted widespread attention. The study shows that for patients with early or locally advanced HR+/HER2- breast cancer, the objective response rate (ORR) of Dalpiciclib combined with Letrozole is 81%. Furthermore, an evaluation of the treatment's effectiveness after 4 cycles holds potential as an optional scheme for neoadjuvant chemotherapy-free treatment. This publication has invited Professor Hong Zong from the First Affiliated Hospital of Zhengzhou University to provide a detailed introduction to this study.
SABCS 2023 | Professor Jiayi Chen : Escalating or De-escalating — Focusing on the Latest Developments in the Field of Breast Cancer Radiotherapy

SABCS 2023 | Professor Jiayi Chen : Escalating or De-escalating — Focusing on the Latest Developments in the Field of Breast Cancer Radiotherapy

2024.04.16
The 46th San Antonio Breast Cancer Symposium (SABCS 2023) was held in San Antonio, Texas, where numerous significant studies were presented. Oncology Frontier had the privilege of inviting Professor Jiayi Chen from the Department of Radiation Oncology at Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, to share the latest developments in the field of breast cancer radiotherapy presented at this SABCS conference.
SABCS Researchers Discuss丨Chemotherapy-Free Triple Combination for Advanced Triple-Positive Breast Cancer: HER2 Dual Antibody + CDK4/6i + Fulvestrant

SABCS Researchers Discuss丨Chemotherapy-Free Triple Combination for Advanced Triple-Positive Breast Cancer: HER2 Dual Antibody + CDK4/6i + Fulvestrant

2024.04.16
Numerous studies have confirmed the therapeutic benefits of combining anti-HER2 therapy with endocrine treatment in patients with advanced triple-positive breast cancer (HR+/HER2+). With the enrichment of new endocrine targeting treatments and anti-HER2 treatment schemes in recent years, there has been exploration into other combination schemes, which are hopeful in providing more effective and less toxic "chemotherapy-free" combination treatments for such patients. At the recently held 46th San Antonio Breast Cancer Symposium (SABCS 2023), Professor Santiago Escrivá-de-Romani from the Vall d'Hebron University Hospital/Vall d'Hebron Institute of Oncology in Spain reported a Phase 2a study using a novel HER2 dual-specific antibody (zanidatamab) combined with palbociclib and fulvestrant to treat advanced triple-positive breast cancer, achieving positive anti-tumor activity and good safety.
SABCS Researchers Discuss | DEBBRAH Study: T-DXd Treatment for Leptomeningeal Metastatic Breast Cancer

SABCS Researchers Discuss | DEBBRAH Study: T-DXd Treatment for Leptomeningeal Metastatic Breast Cancer

2024.04.15
The clinical treatment of breast cancer with leptomeningeal metastasis is extremely challenging, with patients surviving only a few months. Currently, intrathecal medication is the main treatment for leptomeningeal metastasis, but it comes with a high risk of bleeding and infection; finding effective systemic treatment drugs has been a hot topic of research in recent years. At the 46th San Antonio Breast Cancer Symposium (SABCS 2023) held recently, Professor Marta Vaz Batista from the Doutor Fernando Fonseca EPE Hospital in Portugal reported the results from Cohort 5 of the Phase II DEBBRAH study, which evaluated the efficacy and safety of T-DXd (trastuzumab deruxtecan) in patients with HER2-positive and HER2-low Advanced Breast Cancer (ABC) with brain metastasis (BM) and/or Leptomeningeal Carcinomatosis (LMC).
Insights from Dr. Charles Flexner on Replacing Oral HIV Medications with Long-acting Drugs

Insights from Dr. Charles Flexner on Replacing Oral HIV Medications with Long-acting Drugs

2024.04.13
In recent years, there have been many groundbreaking developments in the prevention and treatment of HIV infections with long-acting formulations. The LATITUDE study on cabotegravir/rilpivirine for patients with poor adherence was reported in the clinical LBA at the CROI conference. Additionally, the conference featured several special sessions discussing how to optimize the use of long-acting formulations. Dr. Charles Flexner from the Johns Hopkins University shared his views on whether long-acting formulations could replace oral medications in an interview with Infectious Disease Frontier.
Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention

Insights from Dr. Khalil Ghanem on the Challenges and Future of Syphilis Diagnosis, Treatment, and Prevention

2024.04.13
As the incidence of syphilis continues to rise, clinicians are faced with an increasing number of patients with complex clinical presentations, posing significant challenges in patient management. At the 31st Conference on Retroviruses and Opportunistic Infections (CROI), Dr. Khalil Ghanem from the Johns Hopkins University School of Medicine delivered a keynote on the diagnosis and treatment of syphilis. In this issue of Infectious Disease Frontier, we are fortunate to have Dr. Ghanem discuss the diagnostic challenges of neurosyphilis, the value of the DoxyPEP prevention strategy, and the future outlook for syphilis management.